Effect of medroxyprogesterone acetate on the efficiency of an oral protein-rich nutritional support in HIV-infected patients

Abstract

-We have examined the effect of a medroxyprogesterone therapy in HIV-infected patients under appropriate nutrition for anabolism. The experiments were performed on 12 men (mean age 40 y), HIV seropositive but free of any clinically active opportunistic infection for at least one month. The patients underwent a 2-week baseline diet period (1.2 g protein·kg -1 body weight (BW)·d ). Indeed HIV-infected patients showed deficiencies in these amino acids. They were randomly divided into groups I and II under double-blinded condition. Group II was given medroxyprogesterone acetate (0.4 g·d -1 ) during the last 3 weeks whereas group I received a placebo. All the patients significantly increased their body weight (P < 0.05) during the experimental periods. Those under medroxyprogesterone tended to show a higher but not significant weight gain (+3.1 ± 1.0 kg in group II and +1.9 ± 0.3 kg in group I). Blood free amino acids were used as rough indicators of amino acid utilization and were analyzed prior and during acute 150 min intravenous infusion of a complete glucose-amino acid mixture. This test was done before and at the end of the experimental periods. Basal essential blood free amino acids were similar in the two groups and did not change during the experimental period. Most essential amino acids increased Reprod. Nutr. Dev. 43 (2003) 203-214 203

Progesterone therapy for the treatment of non-cancer cachexia: a systematic review

“…The vast majority of studies looked at MA, with only one using medroxyprogesterone 33. Dose of MA was variable (range: 40 mg–800 mg a day, most common: 800 mg a day).…”

Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel

“…Although lipogenesis is a hallmark of most cancers, some breast cancer cells produce large amounts of lipids in response to the female hormone progesterone (Chalbos et al, 1984; Menendez et al, 2007). Progesterone and its analogues (progestins) are also implicated in weight gain (Kalkhoff 1982; Rochon et al, 2003; Shirling et al, 1981; Tuttle et al, 1974), diabetes (Meyer, III et al, 1985; Picard et al, 2002) and in breast cancer risk (Nelson et al, 2002; Rossouw et al, 2002). Estrogen plus progestin combined therapy is also associated with increased breast cancer mortality (Chlebowski et al, 2010), underscoring the effect of hormones on adverse outcomes in breast cancer.…”